LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization ... Outlook Therapeutics’ commercialization strategy, ...
Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company developing novel ...
Mr. Iwicki stated, “I am proud of the work we have done at KALA utilizing our MSC-S platform, and I am very excited about the potential of our lead product candidate, KPI-012 for the treatment of PCED ...
STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, ...
furthers its VerifyUTM commercialization strategy that was announced today by the National Football League Alumni (NFLA). The Web 3.0 project is with the historic and World-renowned NFLA in a 3 ...
KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
Investing News Network on MSN2d
What is In-Licensing?When it comes to investing in pharmaceutical companies, looking at pipelines and research and development prospects is ...
Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally ...
Ms. Brege brings over a decade of experience with the Company, and has extensive knowledge of Pacira’s operations, strategy and unique ... multiple functions including sales and marketing, business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback